Literatur
- 1
Creutzfeldt W.
The incretin concept today.
Diabetologia.
1979;
16
75-85
- 2
Nauck M, Stöckmann F, Ebert R et al.
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
Diabetologia.
1986;
29
46-52
- 3
Nauck M A, Heimesaat M M, Orskov C et al.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic
human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
J Clin Invest.
1993;
91
301-307
- 4
Gallwitz B.
The value of incretin based therapies.
Dtsch Med Wochenschr.
2009;
134
1062-1066
- 5
Farilla L, Bulotta A, Hirshberg B et al.
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness
of freshly isolated human islets.
Endocrinology.
2003;
144
5149-5158
- 6
Holmann R R.
Assessing the potential for alpha-glucosidase inhibitors in prediabetic states.
Diabetes Res Clin Pract.
1998;
40 (Suppl)
S 21-S 25
- 7
Turner R C, Cull C A, Frighi V et al.
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2
diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective
Diabetes Study (UKPDS) Group.
JAMA.
1999;
281
2005-2012
- 8
Unger R H.
Glucagon physiology and pathophysiology.
N Engl J Med.
1971;
285
443-449
- 9
Del Prato S, Marchetti P.
Beta- and alpha-cell dysfunction in type 2 diabetes.
Horm Metab Res.
2004;
36
775-781
- 10
Deacon C F, Nauck M A, Toft-Nielsen M et al.
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly
degraded from the NH2-terminus in type II diabetic patients and in healthy subjects.
Diabetes.
1995;
44
1126-1131
- 11
Mentlein R, Gallwitz B, Schmidt W E.
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide,
peptide histidine methionine and is responsible for their degradation in human serum.
Eur J Biochem.
1993;
214
829-835
- 12
Gallwitz B.
Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.
Drug Saf.
2010;
33
87-100
- 13
Vilsboll T.
Liraglutide: a new treatment for type 2 diabetes.
Drugs Today.
2009;
45
101-113
- 14
Ahren B.
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin
or saxagliptin – diabetes control and potential adverse events.
Best Pract Res Clin Endocrinol Metab.
2009;
23
487-498
- 15
Klonoff D C, Buse J B, Nielsen L L et al.
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers
in patients with type 2 diabetes treated for at least 3 years.
Curr Med Res Opin.
2008;
24
275-286
- 16
Drucker D J, Nauck M A.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4
inhibitors in type 2 diabetes.
Lancet.
2006;
368
1696-1705
- 17
Ristic S, Bates P C.
Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for
treatment of patients with type 2 diabetes.
Drugs Today.
2006;
42
519-531
- 18
Matthaei S, Bierwirth R, Fritsche A et al.
Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based
guideline of the German Diabetes Association.
Exp Clin Endocrinol Diabetes.
2009;
117
522-557
Prof. Dr. med. Baptist Gallwitz
Medizinische Klinik IV · Universitätsklinikum Tübingen
Otfried-Müller-Straße 10
72076 Tübingen
Email: baptist.gallwitz@med.uni-tuebingen.de